168 related articles for article (PubMed ID: 30334977)
1. Change in standardized uptake values in delayed 18F-FDG positron emission tomography images in hepatocellular carcinoma.
Oksuzoglu K; Ones T; Ozguven S; Inanir S; Turoglu HT; Bozkurtlar E; Celikel CA; Erdil TY
Medicine (Baltimore); 2018 Oct; 97(42):e12817. PubMed ID: 30334977
[TBL] [Abstract][Full Text] [Related]
2. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
3. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
[TBL] [Abstract][Full Text] [Related]
4. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial Experience.
Hectors SJ; Wagner M; Besa C; Huang W; Taouli B
Contrast Media Mol Imaging; 2018; 2018():5638283. PubMed ID: 30402045
[TBL] [Abstract][Full Text] [Related]
6. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
[TBL] [Abstract][Full Text] [Related]
7. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma.
Lin WY; Tsai SC; Hung GU
Nucl Med Commun; 2005 Apr; 26(4):315-21. PubMed ID: 15753790
[TBL] [Abstract][Full Text] [Related]
8. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
Park S; Kim TS; Kang SH; Kim HB; Park JW; Kim SK
Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-induced modulation of glucose transporter expression impacts
Xia H; Chen J; Gao H; Kong SN; Deivasigamani A; Shi M; Xie T; Hui KM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):787-797. PubMed ID: 31832727
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor.
Koyama K; Okamura T; Kawabe J; Ozawa N; Higashiyama S; Ochi H; Yamada R
Ann Nucl Med; 2002 May; 16(3):169-76. PubMed ID: 12126041
[TBL] [Abstract][Full Text] [Related]
12. Value of
Wu B; Zhang Y; Tan H; Shi H
Abdom Radiol (NY); 2019 Jul; 44(7):2430-2435. PubMed ID: 30944961
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H
Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070
[TBL] [Abstract][Full Text] [Related]
14. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
[TBL] [Abstract][Full Text] [Related]
16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
17. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
18. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and
Rhee WJ; Hwang SH; Byun HK; Yun M; Han KH; Seong J
Liver Int; 2017 Apr; 37(4):592-599. PubMed ID: 27804192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
